New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
09:32 EDTNYMXNymox announces positive efficacy results in Phase 3 trial of NX-1207
Nymox announced new positive efficacy data for U.S. Study NX02-0022, the company's repeat injection study of NX-1207 for BPH. Analysis of symptomatic improvement from repeat injection over a 1 to 2 year period showed a mean improvement of 8.2 points in the AUA BPH Symptom Index Score. Evaluation of safety data from this study confirmed that NX-1207 reinjection treatment was well-tolerated by patients, did not impair sexual function, and has not shown any drug-related significant side effects. Participants in the clinical trial consisted of 160 consecutively treated men who had previously completed participation in an NX-1207 trial for BPH and who volunteered for a subsequent open label injection of NX-1207.
News For NYMX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 27, 2015
10:14 EDTNYMXNymox trading resumes, shares up $1.33 to $2.60
Subscribe for More Information
09:31 EDTNYMXNymox Phase 3 NX-1207 extension trial meets primary endpoint
Subscribe for More Information
09:17 EDTNYMXNymox trading halted, pending news
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use